MedPath

Reboxetine

Generic Name
Reboxetine
Drug Type
Small Molecule
Chemical Formula
C19H23NO3
CAS Number
71620-89-8
Unique Ingredient Identifier
947S0YZ36I
Background

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

Indication

For the treatment of clinical depression.

Associated Conditions
Major Depressive Disorder (MDD)
Associated Therapies
Maintenances
Clinical Trials
Related News

Reboxetine for Sleep Apnoea After ENT Surgery

Phase 2
Recruiting
Conditions
Sleep Apnea, Obstructive
Interventions
Drug: Placebo
First Posted Date
2023-08-07
Last Posted Date
2024-10-03
Lead Sponsor
Flinders University
Target Recruit Count
20
Registration Number
NCT05978505
Locations
🇦🇺

Flinders, Private and Public Hospitals and Flinders University, Bedford Park, South Australia, Australia

The Role of the Brain in Mental and Physical Fatigue

Phase 3
Recruiting
Conditions
Fatigue
Interventions
First Posted Date
2023-05-30
Last Posted Date
2023-05-30
Lead Sponsor
Vrije Universiteit Brussel
Target Recruit Count
62
Registration Number
NCT05880342
Locations
🇧🇪

Brussels Labo voor Inspanning & Topsport U-residence, Brussels, Belgium

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

Phase 2
Recruiting
Conditions
Posttraumatic Stress Disorder
Interventions
Drug: Placebo
First Posted Date
2021-11-24
Last Posted Date
2025-03-27
Lead Sponsor
University of Haifa
Target Recruit Count
53
Registration Number
NCT05133804
Locations
🇮🇱

University of Haifa, Haifa, Israel

🇮🇱

Lev HaSharon Mental Health Center, Netanya, Israel

🇮🇱

Emek Medical Center, Afula, Israel

Studying the Role of Brain Molecules for Decision Making

Not Applicable
Completed
Conditions
Decision Making
Healthy
Interventions
Drug: Placebo gum
Drug: Placebo pill
First Posted Date
2020-05-12
Last Posted Date
2024-05-08
Lead Sponsor
University of Zurich
Target Recruit Count
160
Registration Number
NCT04384562
Locations
🇨🇭

University of Zurich, Zurich, Switzerland

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Placebos
First Posted Date
2020-05-01
Last Posted Date
2020-05-01
Lead Sponsor
University of Zurich
Target Recruit Count
120
Registration Number
NCT04371146
Locations
🇨🇭

University of Zurich, Zurich, Switzerland

Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects

Phase 1
Completed
Conditions
Stress Urinary Incontinence
Fecal Incontinence
Interventions
Drug: Placebo oral tablet
First Posted Date
2019-09-20
Last Posted Date
2021-06-09
Lead Sponsor
University Hospital Bispebjerg and Frederiksberg
Target Recruit Count
24
Registration Number
NCT04097288
Locations
🇩🇰

Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Placebo oral tablet
First Posted Date
2019-05-21
Last Posted Date
2020-06-16
Lead Sponsor
University of Oxford
Target Recruit Count
107
Registration Number
NCT03957174
Locations
🇬🇧

Dept of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Antidepressants and Bone Mineral Density

Phase 3
Completed
Conditions
Bone Mineral Density Quantitative Trait Locus 7
Interventions
Behavioral: control
First Posted Date
2014-07-01
Last Posted Date
2014-07-01
Lead Sponsor
Guiyang Medical University
Target Recruit Count
203
Registration Number
NCT02179268

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Phase 4
Conditions
Schizophrenia
Interventions
First Posted Date
2011-02-21
Last Posted Date
2011-02-21
Lead Sponsor
Fundació Sant Joan de Déu
Target Recruit Count
249
Registration Number
NCT01300364
Locations
🇪🇸

Parc Sanitari Sant Joan de Déu, Sant Boi Llobregat, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy